Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PureTech Heath founded entity Vor has entered an exclusive licensing agreement with the National Cancer Institute.
This agreement covers the group's intellectual property related to clinical stage cancer treatments of anti-CD33 chimeric antigen receptor T-Cell candidates.
It is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with acute myeloid leukaemia.
At 1:11pm: (LON:PRTC) Puretech Health PLC share price was +7.5p at 245.5p